BNP Paribas Financial Markets
CLYM icon

BNP Paribas Financial Markets’s Climb Bio CLYM Stock Holding History

BNP Paribas Financial Markets’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.6K Sell
5,568
-23,560
-81% -$243K ﹤0.01% 4709
2026
Q1 		$200K Buy
29,128
+28,615
+5,578% +$165K ﹤0.01% 4052
2025
Q4 		$2.05K Sell
513
-1,341
-72% -$3.22K ﹤0.01% 5346
2025
Q3 		$3.73K Sell
1,854
-5,815
-76% -$10.8K ﹤0.01% 5122
2025
Q2 		$9.51K Buy
7,669
+1,906
+33% +$2.37K ﹤0.01% 4852
2025
Q1 		$7.03K Sell
5,763
-38,130
-87% -$61.8K ﹤0.01% 4794
2024
Q4 		$79K Buy
+43,893
New +$159K ﹤0.01% 4247
2022
Q4 		– Sell
-158
Closed -$510 – 4707
2022
Q3 		$510 Buy
+158
New +$504 ﹤0.01% 4515

Other funds holding CLYM

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BNP Paribas Financial Markets's CLYM Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Climb Bio (CLYM) stake by 81% in Q2 2026, selling an estimated $243K and leaving 5,568 shares worth $72.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4709.

BNP Paribas Financial Markets first reported a position in CLYM in Q3 2022 and has held it in 8 quarters since. The position peaked at $200K in Q1 2026. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • BNP Paribas Financial Markets held 5,568 shares of Climb Bio worth $72.6K as of Q2 2026.
  • BNP Paribas Financial Markets sold 23,560 Climb Bio shares in Q2 2026, an estimated $243K.
  • Climb Bio made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4709 holding.
  • BNP Paribas Financial Markets first reported a position in Climb Bio in Q3 2022 and has held it in 8 quarters since.
  • BNP Paribas Financial Markets's Climb Bio position peaked at $200K in Q1 2026.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.